融捷健康(300247) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥158,259,198.06, representing a 28.43% increase compared to ¥123,228,041.25 in the same period last year[5] - Net profit attributable to shareholders was ¥11,189,537.80, a significant increase of 116.73% from ¥5,162,844.88 year-on-year[5] - Basic earnings per share rose to ¥0.0139, up 117.19% from ¥0.0064 in the same period last year[5] - The company's net profit for the current period is CNY 18,327,304, representing an increase of 48.3% compared to CNY 12,373,896.73 in the previous period[25] - Operating profit increased to CNY 25,233,202.51, up 31.1% from CNY 19,238,586.03 year-over-year[25] - Total revenue from sales of goods and services reached CNY 149,863,285.01, an increase of 13.9% compared to CNY 131,546,519.87 in the previous period[28] - The total comprehensive income for the current period is CNY 16,808,961.24, compared to CNY 12,208,652.83 in the previous period[26] Cash Flow - The net cash flow from operating activities surged to ¥46,906,552.61, marking a 635.77% increase from ¥6,375,180.75 in the previous year[5] - The net cash flow from operating activities improved significantly to CNY 46,906,552.61, compared to CNY 6,375,180.75 in the previous period[28] - Investment activities generated a net cash flow of CNY 3,368,744.96, a turnaround from a negative cash flow of CNY -13,885,986.01 in the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,185,304,298.39, a slight decrease of 0.13% from ¥1,186,803,628.67 at the end of the previous year[5] - The company's total assets decreased slightly to CNY 1,185,304,298.39 from CNY 1,186,803,628.67 at the beginning of the year[23] - The total liabilities decreased to CNY 139,722,035.41 from CNY 158,030,326.94, showing a reduction of approximately 11.6%[23] - The total equity attributable to the parent company increased to CNY 998,626,593.49 from CNY 988,955,398.44, reflecting a growth of 1.7%[23] Operating Costs and Expenses - The company reported a 39.72% increase in operating costs, amounting to an increase of ¥31,636,500.00 due to higher sales from its U.S. subsidiary[12] - The total operating costs amounted to CNY 137,305,140.63, up from CNY 105,672,960.28, reflecting a year-over-year increase of 29.9%[24] - Research and development expenses were CNY 2,065,738.44, a decrease of 22.5% from CNY 2,667,178.09 in the previous period[25] Inventory and Accounts Payable - Inventory decreased by ¥45,585,600.00, reflecting a 24.43% decline, mainly due to sales of previously held inventory by the U.S. subsidiary[10] - The company reported a decrease in inventory from CNY 186,574,736.48 to CNY 140,989,089.00, a reduction of approximately 24.4%[22] - The accounts payable decreased from CNY 52,696,877.97 to CNY 40,690,282.01, indicating a decline of about 22.8%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 38,439[17] Foreign Currency and Other Adjustments - The company reported a foreign currency translation difference of CNY -986,922.79, compared to CNY -165,243.90 in the previous period[26]